Rifampin in treatment of acute Idiopathic Central Serous Chorioretinopathy

Effect of oral Rifampin in anatomic improvment of patients with acute Idiopathic Central Serous Chorioretinopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012072810414N1

Enrollment

Registered

2013-01-23

Start date

2012-07-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Central Serous Chorioretinopathy. Separation of retinal layers

Interventions

Intervention 1: Treatment :each patient receives rifampin 600 mg (weight< 50 kg received rifampin 300 mg) in Single dose one hour before breakfast one month. Intervention 2: Placebo:each patient rece

Treatment - Drugs

Placebo

Treatment :each patient receives rifampin 600 mg (weight< 50 kg received rifampin 300 mg) in Single dose one hour before breakfast one month.

Placebo:each patient receives Placebo in Single dose One hour before breakfast one month.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Cases of Idiopathic Central Serous Chorioretinopathy ( CSCR) with visual symptoms less than one month in one or both eyes; CSCR confirmed by Fluorescien Angiography (F/A) and Optical CoherenceTomography (OCT) including Central Serous Retinal detachment and or Retinal Pigment epithelial detachment without evidence of any other possible case of exudation. exclusion criteria: Pregnancy and Lactation; Any Contraindication of Rifampin usage including liver disorders ; Patients who used Corticosteroid(Oral, injection, oint, spray) in last 6 months; Any clinical or F/A or OCT sign of Chronic or recurrent CSCR; Using drugs which have interaction with rifampin(during study period); Using 5-phosphodiestrase inhibiting drugs in last 6 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anatomical Changes. Timepoint: every month till 3 months. Method of measurement: Clinical exam and Optical Coherence Tomography.;Visual Changes. Timepoint: every month till 3 months. Method of measurement: Snelen Chart.	—

Secondary

Measure	Time frame
Serum Cortisol Level. Timepoint: every month till 2 months after intervention. Method of measurement: Measuring Serum Cortisol Level at 8 AM.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR YOUSEF ALIZADEH

GUILAN UNIVERSITY OF MEDICAL SCIENCES

ysf_alizadeh@yahoo.com+98 13 1223 6886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026